Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $65.00 USD
Change Today 0.00 / 0.00%
Volume 0.0
As of 8:10 PM 08/25/15 All times are local (Market data is delayed by at least 15 minutes).

alseres pharmaceuticals inc (ALSE) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/4/14 - $400.00
52 Week Low
06/26/15 - $65.00
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

alseres pharmaceuticals inc (ALSE) Related Businessweek News

No Related Businessweek News Found

alseres pharmaceuticals inc (ALSE) Details

Alseres Pharmaceuticals, Inc., a biotechnology company, together with its subsidiaries, focuses on developing therapeutic and diagnostic products primarily for disorders in the central nervous system. The company’s clinical product candidate, Altropane, is a molecular imaging program, which focuses on the diagnosis of Parkinsonian syndromes, including Parkinson’s disease, and dementia with lewy bodies. It has a license agreement with Navidea Biopharmaceuticals, Inc. to research, develop, and commercialize Altropane, an Iodine-123 radiolabeled imaging agent for the diagnosis of Parkinson’s disease and movement disorders. The company was formerly known as Boston Life Sciences, Inc. and changed its name to Alseres Pharmaceuticals, Inc. in June 2007. Alseres Pharmaceuticals, Inc. was founded in 1972 and is based in Auburndale, Massachusetts.

3 Employees
Last Reported Date: 04/10/14
Founded in 1972

alseres pharmaceuticals inc (ALSE) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: $401.6K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $267.8K
Compensation as of Fiscal Year 2013.

alseres pharmaceuticals inc (ALSE) Key Developments

Alseres Pharmaceuticals, Inc. will Change its Ticker to ALSE from ALSED

Effective January 29, 2015, Alseres Pharmaceuticals, Inc. will change its Pink Sheets LLC stock ticker symbol to ALSE from ALSED.

Alseres Pharmaceuticals, Inc. Files Certificate of Amendment to the Certificate of Incorporation

On November 17, 2014, pursuant to the authorization of the Board of Directors of Alseres Pharmaceuticals, Inc., filed a Certificate of Amendment to the Certificate of Incorporation of the Company with the Delaware division of Corporations. The amendment is set out below: Section 1. Reverse Stock Split. Effective upon the filing of this Certificate of Amendment of the Certificate of Incorporation of the Corporation with the Secretary of State of the State of Delaware (the Effective Time), each 5,000 shares of Common Stock of the Corporation issued and outstanding immediately prior to the Effective Time (Old Common Stock) shall automatically be combined and converted, without any action on the part of the holder thereof, into one (1) share of fully paid and non-assessable Common Stock of the Corporation (the Reverse Stock Split). This Reverse Stock Split shall be effected on a certificate by certificate basis, and no fractional shares shall be issued as a result of this Reverse Stock Split. In lieu thereof, the Corporation shall pay to each holder of any such fractional share an amount equal to the fair value thereof at the Effective Time as determined in good faith by the Board of Directors. Each certificate that, prior to the Effective Time, represented shares of Old Common Stock shall, from and after the Effective Time, represent that number of whole shares of Common Stock into which the shares of Old Common Stock represented by such certificate have been reclassified pursuant to this Certificate of Amendment. All number of shares and all amounts stated on a per share basis contained in this Certificate of Amendment are stated after giving effect to the Reverse Stock Split and no further adjustment shall be made as a consequence of the Reverse Stock Split. Appropriate adjustments to reflect the effect of the Reverse Stock Split are to be made to any outstanding options to purchase the Old Common Stock of the Corporation. Section 2, the Corporation is authorized to issue two classes of stock to be designated Common Stock and Preferred Stock. The total number of shares of Common Stock that the Corporation is authorized to issue is 80,000,000 shares, par value $0.01 per share and 1,000,000 shares of Preferred Stock par value $0.01 per share.

Alseres Pharmaceuticals, Inc. Files Form 15

Alseres Pharmaceuticals, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its common stock under the Securities Exchange Act of 1934, as amended.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALSE:US $65.00 USD 0.00

ALSE Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALSE.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALSE Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 4,183.5x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALSERES PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at